News
& Events
News
& Events

News
& Events

Inversago Pharma receives $7 million in series A financing

MONTREAL (CANADA) – 25 July 2018 – Today Inversago Pharma Inc. (“Inversago”) announced that it has secured a $7 million series A financing to pursue its development plan and advance its CB1 platform as a potent treatment for targeted diseases.

Read more

Inversago Pharma’s CEO François Ravenelle will attend Biotech Showcase

Inversago Pharma’s CEO François Ravenelle will attend Biotech Showcase, January 8-10th, 2018 in San Francisco, CA.

Inversago Pharma’s CEO François Ravenelle will attend RESI Boston event

Inversago Pharma’s CEO François Ravenelle will attend RESI Boston event on September 26th.

Inversago Pharma announces the execution of license agreement with US NIH’s CB1 inverse agonist technology.

Inversago Pharma annonce la prise d’effet de l’accord d’octroi de licence conclu avec les National Institutes of Health (NIH) des États-Unis concernant leur technologie d’agonistes inverses du CB1.